Cargando…
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
Targeted radiopharmaceuticals for therapeutic use deliver radionuclides directly to tumor anywhere in the body, and therefore, have renewed interest for clinical development in women with disseminated chemorefractory ovarian cancers. About two in every five women with advanced stage ovarian cancer o...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448015/ https://www.ncbi.nlm.nih.gov/pubmed/30984615 http://dx.doi.org/10.3389/fonc.2019.00180 |